Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.53 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 8/20 | 0.37 |
| ▸ | HTR2B | P41595 | 5/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 5/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17356809 | 0.89 | PNMT (0.46) | PNMTCHRNB2CHRNA4TAS1R3TAS1R1 | |
| SCHEMBL17356789 | 0.80 | TAS1R3 (0.44) | PNMTCHRNB2CHRNA4TAS1R3TAS1R1 | |
| SCHEMBL17356806 | 0.79 | HTR2C (0.50) | PNMTCHRNB2CHRNA4HTR2CHTR2B | |
| SCHEMBL17356805 | 0.70 | PNMT (0.43) | PNMTCHRNB2CHRNA4TAS1R3TAS1R1 | |
| SCHEMBL14135945 | 0.70 | PNMT (0.42) | PNMTCHRNB2CHRNA4TAS1R3TAS1R1 | |
| SCHEMBL13632697 | 0.69 | PNMT (0.49) | PNMTCHRNB2CHRNA4HTR2CGRM2 | |
| SCHEMBL17356804 | 0.69 | HTR2C (0.47) | PNMTTAS1R3TAS1R1TAS1R2HTR2C | |
| SCHEMBL21067929 | 0.69 | PNMT (1.00) | PNMTCHRNB2CHRNA4HTR2CHTR2B | |
| SCHEMBL17356798 | 0.69 | GAA (0.51) | PNMTTAS1R3TAS1R1TAS1R2HTR2C | |
| SCHEMBL25044023 | 0.67 | PNMT (0.43) | PNMTCHRNB2CHRNA4TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170313792-A1 | METHOD FOR PRODUCING POLAR GROUP-CONTAINING OLEFIN POLYMER | THE UNIVERSITY OF TOKYO (JP) | 2017-11-02 | — | — | US | disclosed |
| US-9499644-B2 | Production method of polar group-containing olefin polymers | SHOWA DENKO K.K. (JP) | 2016-11-22 | — | — | US | disclosed |
| US-20150368376-A1 | PRODUCTION METHOD OF POLAR GROUP-CONTAINING OLEFIN POLYMERS | SHOWA DENKO K.K. (JP) | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368376-A1 | PRODUCTION METHOD OF POLAR GROUP-CONTAINING OLEFIN POLYMERS | OR10J3, OPRM1, ORC3 | PNMT 316/4885CHRNB2 1890/4885CHRNA4 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.